Yu-Wei Chen, MD, MS

Pleased to share our study published in @CCR_AACR 👉 doi.org/10.1158/1078-0… 📍NF2 loss (merlin deficiency) in RCC delineates a distinctly aggressive biological phenotype: ⏫ heightened proliferative capacity, profound immune dysregulation, and recurrent alterations in cell cycle and DNA damage–response pathways. ⏬ limited efficacy of immunotherapy further underscores the pressing need for biomarker-driven, molecularly tailored therapeutic strategies. #Oncology #cancer #kidneycancer @DrChoueiri @MikeSerzanMD @WeiweiBian @OncoAlert @DanaFarberNews @DanaFarber_GU @AnkaraUni

🔬 @BraunMDPhD breaking down the determinants of anti-tumor immunity in #RCC at #AACRKidney2026 The immunity cycle in kidney cancer is not one-size-fits-all 🧬 Key themes: ✅ Tumor antigenicity shapes T cell recognition ✅ Immune contexture varies by molecular subtype ✅ Understanding WHERE the cycle breaks = rational combo design 💡 In ccRCC, the bottleneck is not always priming. Sometimes it's trafficking. Sometimes it's dysfunction in the TME. Knowing the step matters for choosing the right intervention. We keep treating IO resistance as one problem. Braun's framework reminds us it's many. 🎯 #KidneyCancer #RCC #Immunotherapy #GUOnc #AACRKidney2026

(2/3) Elevated BMI has variably been associated with improved response to ICI in mccRCC. We show that higher skeletal muscle mass and subQ adiposity are associated with shorter PFS with nivo + ipi. Similar to work from @MRHarrisonMD and Duke team.

@DrChoueiri @DanaFarber_GU @MDAndersonNews @Clara__Steiner @lilli_ash @ChadTangMD @DrYukselUrun @yekeduz_emre KIM-1 and ctDNA (next-generation, genome-wide assay) are complementary in oligometastatic RCC, and the K-COMPASS model identifies patients with best outcomes after metastasis directed therapy. @ChadTangMD @PavlosMsaouel Check it out in @EUplatinum: sciencedirect.com/science/articl…

@Jani_Chinmay @CCR_AACR @DrRanaMcKay @EliTran97 Congrats @Jani_Chinmay for leading the work!!!

Our new study in @CCR_AACR characterizes Longitudinal Molecular Changes in ctDNA in mCRPC 🧬@DrRanaMcKay @EliTran97 We demonstrate dynamic tumor evolution under therapeutic pressure and identify AR alterations as consistent drivers of resistance and inferior outcomes. Using real-world GuardantINFORM data @GuardantHealth: • Rising mutations after ARPi, PARPi, and taxanes • Enrichment of AR alterations/mutations post-therapy • AR alterations associated with worse OS, TTD, and TTNT. Real-time liquid biopsy/ctDNA may help guide personalized treatment strategies before overt clinical resistance emerges. @SylvesterCancer @HemOncMiami @YuWeiChenMD @UCSDCancer #ProstateCancer #mCRPC #ctDNA #LiquidBiopsy #PrecisionOncology news.med.miami.edu/reading-cancer…

@OncLive @ASCO @CParkMD @arnabguonc @AJangMD @mm_zerey @abbylgrier @JeffreyYZhong @ArashRezazadeh6 Always nice to connect with friends/mentors/colleagues at conferences!

⭐️ Fun day catching up with friends and colleagues 😄🧬 @ASCO #GU26 #OncLiveTakeover @CParkMD @ASCO #GU26 @arnabguonc @AJangMD @YuWeiChenMD @mm_zerey @abbylgrier @JeffreyYZhong @ArashRezazadeh6

Our poster at #GUASCO looking at clinical & pathologic outcomes in pts undergoing deferred consolidative nephrectomy (dCN) after IO-based tx. for RCC. Is there still a role and goal for dCN in the IO era? Follow the 🧵

Now enrolling through @ALLIANCE_org - STRIKE! (A032201) exploring the role of Tivozanib with pembrolizumab following resection of ccRCC - check out our TIP at #GU26 @ASCO @DanaFarber_GU clinicaltrials.gov/study/NCT06661…

Honored to serve as discussant for these important RCC oral abstracts: LS-011, RAMPART PRO, and LS-022. 🩵 Together, these studies reflect a bigger theme in RCC: intensification and rational combination therapy across the treatment landscape to improve outcomes, from refractory disease to the adjuvant setting. 📈🧬 I’m excited to approach these data with curiosity, highlight the efficacy signals in today’s clinical context, and dig into the key questions that still remain around patient selection, toxicity, durability, and how best to apply these strategies in practice. 🎯💬 #ASCOGU26 #GU26 #KidneyCancer #RCC #ClinicalTrials

Congratulations to the Indiana team with @JenniferKingMD and @nabiladra presenting cabozantinib in refractory GCT, CBR 43%, very tough area to make progress, glad to see multiple MOAs advancing to try and bring better options for this patient population

Thoughtful dissection of LS-011 and LS-022 by @katy_beckermann Lots to still consider with adjuvant therapy and post-IO tx decisions (including DOR) are more nuanced.

@MRHarrisonMD showing latest data from the Odyssey RCC registry: greater QOL with IO/IO therapy vs IO/TKI. @DukeCancer @DukeGUCancer

#GU26 Proud to share #ETCTN10483 (IIT): Phase Ib erdafitinib + enfortumab vedotin in FGFR2/3-altered mUC (n=15) post chemo + IO. ORR 93%, median PFS 11.7 mo, OS 23.2 mo. Strong signal of biologic synergy. #BladderCancer #FGFR #ETCTN

Congrats @DrTylerStewart’s excellent discussion on perioperative EV-P results and insights regarding future Her-2 biomaker works for DV #GU26 @ASCO @UCSDCancer @BladderCancerUS @DrRanaMcKay @AdityaBagrodia @AmirSalmasi

@DrTylerStewart @UCSDCancer insightful discussant section ➡️ EV-P new standard in #MIBC but how many adj cycles of EV-P is necessary & can we avoid cystectomy? DV effective but how will it work after EV and clarity around HER2 biomarker needed @OncoAlert #GU26

Survey of >500 PC pts showed caregivers R essential partners, monitoring treatment adherence, mental health, side effects & more. Interestingly, female caregivers more engaged. Pts with no caregiver = the most vulnerable. Thnx Dena Battle @RCCadvocate @DukeCancer

PCWG4 is published! #GU26 Thanks to @ThePCCTC and my co chairs Howard Scher and Mike Morrison and the 65 co-authors of these new trial guidelines! @DukeCancer @JCO_ASCO ascopubs.org/doi/10.1200/JC…

Ab#507 @ASCO #GU26 by #AliMoradi👉bit.ly/4tTeyDA👉Long-term outcomes w/ live bacteria (CBM588) in mRCC #kidneycancer👉addition of CBM588 to frontline ICI Rx👉⬆️ORR & PFS👉supporting upcoming Ph3 @SWOG BIOFRONT study👇 @montypal @OncoAlert @urotoday @KidneyCAN